Relation between dietary fat intake type and serum fatty acid status in children with cystic fibrosis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 55, Issue 5, 2012, Pages 605-611

  Maqbool, Asim ^a   Schall, Joan I ^a   Gallagher, Paul R ^a   Zemel, Babette S ^a   Strandvik, Birgitta ^b   Stallings, Virginia A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

linolenic acid; Cystic fibrosis; Diet; Docosahexaenoic acid fatty acids; Linoleic acid

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; LINOLEIC ACID; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID;

ARTICLE; CALORIC INTAKE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; FAT INTAKE; FATTY ACID BLOOD LEVEL; FEMALE; GAS LIQUID CHROMATOGRAPHY; HUMAN; LIPID ABSORPTION; MAJOR CLINICAL STUDY; MALE; PANCREAS INSUFFICIENCY; PRIORITY JOURNAL; SCHOOL CHILD;

ALPHA-LINOLENIC ACID; ARACHIDONIC ACID; CHILD; CYSTIC FIBROSIS; DIET; DIETARY FATS; DOCOSAHEXAENOIC ACIDS; ENERGY INTAKE; EXOCRINE PANCREATIC INSUFFICIENCY; FEMALE; HUMANS; LINOLEIC ACID; MALE; NUTRITIONAL STATUS;

EID: 84869087168     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182618f33     Document Type: Article

References (49)

1. Clarke SD. The multi-dimensional regulation of gene expression by fatty acids: Polyunsaturated fats as nutrient sensors. Curr Opin Lipidol 2004;15:13-8.
2. Stubbs CD, Smith AD. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta 1984;779:89-137.
3. Kuo PT, Huang NN, Bassett R. The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis of the pancreas. J Pediatr 1962;60:394-403.
4. Strandvik B. Relation between essential fatty acid metabolism and gastrointestinal symptoms in cystic fibrosis. Acta Paediatr Scand Suppl 1989;363:58-63. discussion 63-5:58-63.
5. Strandvik B, Berg U, Kallner A, et al. Effect on renal function of essential fatty acid supplementation in cystic fibrosis. J Pediatr 1989;115:242-50.
6. Strandvik B. Long chain fatty acid metabolism and essential fatty acid deficiency with special emphasis on cystic fibrosis. In: Polyunsaturated Fatty Acid in Human, Nutrition. New York: Raven Press; 1992:159-67.
7. Cawood AL, Carroll MP,Wootton SA, et al. Is there a case for n-3 fatty acid supplementation in cystic fibrosis? Curr Opin Clin Nutr Metab Care 2005;8:153-9.
8. Deleted in proof
9. Coste TC, Armand M, Lebacq J, et al. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin Biochem 2007;40:511-20.
10. Maqbool A, Schall JI, Garcia-Espana JF, et al. Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2008;47:635-44.
11. Walkowiak J, Lisowska A, Blaszczynski M, et al. Polyunsaturated fatty acids in cystic fibrosis are related to nutrition and clinical expression of the disease. J Pediatr Gastroenterol Nutr 2007;45:488-9.
12. Shoff SM, Ahn HY, Davis L, et al. Temporal associations among energy intake, plasma linoleic acid, and growth improvement in response to treatment initiation after diagnosis of cystic fibrosis. Pediatrics 2006; 117:391-400.
13. Lloyd-Still JD, Bibus DM, Powers CA, et al. Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis. Acta Paediatr 1996;85:1426-32.
14. Corey M, McLaughlin FJ,Williams M, et al. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988;41:583-91.
15. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002;35:246-59.
16. Trabulsi J, Ittenbach RF, Schall JI, et al. Evaluation of formulas for calculating total energy requirements of preadolescent children with cystic fibrosis. Am J Clin Nutr 2007;85:144-51.
17. Institute of Medicine (U.S.). Panel on Macronutrients, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Washington, DC: National Academies Press; 2005.
18. Cohen JR, Schall JI, Ittenbach RF, et al. Fecal elastase: Pancreatic status verification and influence on nutritional status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2005;40:438-44.
19. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
20. Gronowitz E, Mellstrom D, Strandvik B. Serum phospholipid fatty acid pattern is associated with bone mineral density in children, but not adults, with cystic fibrosis. Br J Nutr 2006;95:1159-65.
21. Lohman TG, Roche AF, Martorell R. Anthropometric Standardization Reference Manual. Champaign, IL: Human Kinetics Books; 1988.
22. Himes JH, Roche AF, Thissen D, et al. Parent-specific adjustments for evaluation of recumbent length and stature of children. Pediatrics 1985;75:304-13.
23. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data 2000:1-27.
24. Morris AH, Intermountain Thoracic Society. Clinical Pulmonary Function Testing: A Manual of Uniform Laboratory Procedures. 2nd ed. Salt Lake City, UT: Intermountain Thoracic Society; 1984.
25. Gardner RM. Standardization of spirometry: A summary of recommendations from the American Thoracic Society. The 1987 update. Ann Intern Med 1988;108:217-20.
26. Zapletal A, Sama'nek M, Paul T. Lung Function in Children and Adolescents: Methods, Reference Values. Basel; New York: Karger; 1987.
27. Wang X, Dockery DW, Wypij D, et al. Pulmonary function growth velocity in children 6 to 18 years of age. Am Rev Respir Dis 1993; 148:1502-8.
28. Olveira G, Dorado A, Olveira C, et al. Serum phospholipid fatty acid profile and dietary intake in an adult Mediterranean population with cystic fibrosis. Br J Nutr 2006;96:343-9.
29. Colombo C, Bennato V, Costantini D, et al. Dietary and circulating polyunsaturated fatty acids in cystic fibrosis: Are they related to clinical outcomes? J Pediatr Gastroenterol Nutr 2006;43:660-5.
30. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236-8.
31. Rothman K. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-6.
32. Savitz DA, Olshan AF. Multiple comparisons and related issues in the interpretation of epidemiologic data. Am J Epidemiol 1995;142:904-8.
33. Holman RT. The ratio of trienoic:tetraenoic acids in tissue lipids as a measure of essential fatty acid requirement. J Nutr 1960;70:405-10.
34. Panchaud A, Sauty A, Kernen Y, et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomized, crossover placebo-controlled trial. Clin Nutr 2006;25:418-27.
35. Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004;350:560-9.
36. Chen AH, Innis SM, Davidson AG, et al. Phosphatidylcholine and lysophosphatidylcholine excretion is increased in children with cystic fibrosis and is associated with plasma homocysteine, S-Adenosylhomocysteine, and S-Adenosylmethionine. Am J Clin Nutr 2005;81:686-91.
37. Plourde M, Cunnane SC. Extremely limited synthesis of long chain polyunsaturates in adults: Implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab 2007;32:619-34.
38. Brenna JT, Salem N Jr, Sinclair AJ, et al. alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids 2009;80:85-91.
39. Kris-Etherton PM, Taylor DS, Yu-Poth S, et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 2000; 71:179S-88S.
40. Otten JJ, Hellwig JP, Meyers LD. DRI, Dietary Reference Intakes: The Essential Guide to Nutrient Requirements Washington, DC: National Academies Press; 2006.
41. Lipids, sterols, and their metabolites. Jones PJH, Kubow S, Maurice ES, eds. Modern Nutrition in Health and Disease. 10th ed. Philadelphia: Lippincot Williams & Wilkins; 2006:92-122.
42. De Vizia B, Raia V, Spano C, et al. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. JPEN J Parenter Enteral Nutr 2003;27:52-7.
43. Lloyd-Still JD, Johnson SB, Holman RT. Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation. Am J Clin Nutr 1981;34:1-7.
44. Lloyd-Still JD, Powers CA, Hoffman DR, et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: A randomized, controlled study. Nutrition 2006;22:36-46.
45. Van Biervliet S, Devos M, Delhaye T, et al. Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot Essent Fatty Acids 2008;78:109-15.
46. Jumpsen JA, Brown NE, Thomson AB, et al. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J Cyst Fibros 2006;5:77-84.
47. Olveira G, Olveira C, Acosta E, et al. Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Arch Bronconeumol 2010;46:70-7.
48. Oliver C, Jahnke N. Omega-3 fatty acids for cystic fibrosis. Cochrane Database Syst Rev 2011:CD002201.
49. Maqbool A, Strandvik B, Stallings VA. The skinny on tuna fat: Health implications. Public Health Nutr 2011;14:2049-54.